SCHEMBL6348954

SCHEMBL6348954

CCCS(=O)(=O)NCCOc1ccc(C2(O)CCCC2NS(=O)(=O)CCC)cc1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 3/20 0.45
CYP3A4 P08684 1/20 0.45
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
ITGB3 P05106 1/20 0.34
ITGA2B P08514 1/20 0.34
ADAM17 P78536 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6349725 0.97 SLC6A9 (0.44) SLC6A9CYP3A4LMNAHTTMEN1
SCHEMBL6345481 0.94 ALDH1A1 (0.42) SLC6A9CYP3A4LMNAHTTMEN1
SCHEMBL6344428 0.91 ALDH1A1 (0.42) SLC6A9CYP3A4LMNAHTTMEN1
SCHEMBL6355740 0.89 ALDH1A1 (0.45) SLC6A9CYP3A4MEN1KMT2AALDH1A1
SCHEMBL6345333 0.89 MEN1 (0.37) SLC6A9CYP3A4LMNAMEN1KMT2A
SCHEMBL6347185 0.87 SLC6A9 (0.45) SLC6A9CYP3A4LMNAHTTMEN1
SCHEMBL6345791 0.86 ALDH1A1 (0.44) SLC6A9CYP3A4MEN1KMT2AALDH1A1
SCHEMBL6356779 0.86 MEN1 (0.39) SLC6A9CYP3A4LMNAMEN1KMT2A
SCHEMBL6346464 0.84 ADAM17 (0.33) SLC6A9CYP3A4LMNAMEN1KMT2A
SCHEMBL7092690 0.84 SLC6A9 (0.45) SLC6A9CYP3A4LMNAHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US claimed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US claimed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 EP claimed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 WO claimed
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US disclosed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067984-A1 Cyclopentyl sulfonamide derivatives GRIN2A, GRIN1, GRIK5 SLC6A9 217/4885CYP3A4 3693/4885LMNA 4826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.